Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link .

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com .

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit www.acumenpharm.com .

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
AcumenPR@westwicke.com



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS:US
The Conversation (0)

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

"Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Critical Minerals Market Expected to Reach $586 Billion by 2032 as Demand Grows for Supply of Essential Minerals

Critical Minerals Market Expected to Reach $586 Billion by 2032 as Demand Grows for Supply of Essential Minerals

FN Media Group News Commentary - Industry experts project that the global critical minerals market will continue maintaining substantial growth as it has in recent years. The global critical minerals market is experiencing unprecedented growth, primarily driven by the accelerating transition to clean energy technologies. According to the International Energy Agency (IEA), the market size of key energy transition minerals doubled over the past five years, aligning closely with the market size for iron ore mining. This surge is largely attributed to the tripling of lithium demand, a 70% increase in cobalt demand, and a 40% rise in nickel demand between 2017 and 2022, with clean energy applications accounting for significant portions of this demand. The sustainability of the global critical minerals market is increasingly influenced by governmental initiatives aimed at reducing environmental impact and enhancing resource efficiency. A recent report from DataM Intelligence projected that Critical Minerals Market Size reached US$ 328.19 billion in 2024 and is expected to reach US$ 586.63 billion by 2032, growing with a CAGR of 7.53% during the forecast period 2025-2032. The report said: "A notable trend in the critical minerals market is the increasing investment in mineral development, which witnessed a 30% rise in 2022 following a 20% increase in 2021. Lithium saw the sharpest investment increase at 50%, followed by copper and nickel. This investment surge is a response to the soaring demand for minerals like lithium, cobalt, nickel, and copper, driven by the deployment of clean energy technologies such as electric vehicles, wind turbines, and solar panels." Active companies in the markets this week include: SAGA Metals Corp. (OTCQB: SAGMF) (TSX-V: SAGA), TMC the metals company Inc. (NASDAQ: TMC), Critical Metals Corp. (NASDAQ: CRML), Rio Tinto Group (NYSE: RIO), Empire Metals Limited (OTCQX: EPMLF) (LON: EEE).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Heritage Mining Confirms Broad Zone of Gold Mineralization within a Mega-Quartz Vein System

Heritage Mining Confirms Broad Zone of Gold Mineralization within a Mega-Quartz Vein System

(TheNewswire)

VANCOUVER, BC TheNewswire - September 9, 2025 Heritage Mining Ltd. (CSE: HML FRA: Y66) (" Heritage " or the " Company ") is pleased to announce a confirmed broad gold zone within a newly discovered ~74m wide quartz vein system (true width unknown) associated with a magnetic anomaly that extends for ~4km along strike length and up to 200m in width (Figure 1, 2) at its flagship Drayton Black Lake Project. Scout drilling targeted this previously unrecognized magnetic feature at Zone Three Extension, as part of the ongoing 2025 Exploration Scout Drill Program.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Sun Summit Drills 78.0 Meters of 3.72 g/t Gold Including 19.1 Meters of 7.50 g/t Gold at the JD Project, Toodoggone District, B.C.

Sun Summit Drills 78.0 Meters of 3.72 g/t Gold Including 19.1 Meters of 7.50 g/t Gold at the JD Project, Toodoggone District, B.C.

Sun Summit Minerals Corp. (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) ("Sun Summit" or the "Company") is pleased to report results from its first drill hole completed in 2025 at the JD Project, Toodoggone Mining District, north-central British Columbia.

Hole CZ-25-007 returned one of strongest intervals of consistent and near-surface gold mineralization drilled to date at the Creek Zone: 78.0 meters of 3.72 g/t gold starting at 30.0 meters down hole. This interval of near-surface gold mineralization is in an area previously untested by drilling and is interpreted to represent a parallel trend of mineralization north of the Creek Zone where it remains open to the northwest. Follow-up drilling is planned for this season.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×